Management of retinitis pigmentosa by Wharton’s jelly derived mesenchymal stem cells: preliminary clinical results

Table 2 Comparison of BCVA, Visual field MD and Outer Retinal Thickness values at baseline and final examination (6th month)

Parametres	Baseline	Final	p	%95 CI (L, U)
Parametres	X ± SD	X ± SD	p	%95 CI (L, U)
BCVA	70,5 ± 15,71	80,62 ± 16,26	0,01^*	(−12,33, −7,9)
Visual field MD	27,25 ± 3,41	24,72 ± 5,98	0,01^*	(1,05, 4,00)
Outer Retinal Thickness	100,26 ± 15,64	119,11 ± 17,07	0,01^*	(−25,42, −13,26)

BCVA, best-corrected visual acuity; ETDRS, early treatment of diabetic retinopathy study charts (letters point);
MD, mean deviation (dB)
Outer retinal thickness (μm)
%95 CI L and U, 95% confidence interval of the difference (mean)
* Bold: Statistically signigicant

ISSN: 1757-6512